Abstract：
Our study aimed to investigate the clinical features of recurrent preeclampsia (rPE) and evaluate the preventive effect of low-dose aspirin (LDA) in rPE. We retrospectively analyzed the data of 109 patients who experienced preeclampsia in two consecutive pregnancies and delivered at Peking University First Hospital from January 2016 to December 2022. We analyzed the pregnancy outcomes of patients with rPE and assessed whether the use of LDA during pregnancy could improve these outcomes. Our results revealed that patients with rPE had a higher body mass index (BMI) and a higher incidence of diabetes during pregnancy compared to their first onset of preeclampsia (29.01 ± 4.70 kg/m2 vs. 27.13 ± 4.25 kg/m2, P < 0.05; 11.01% vs. 1.83%, P < 0.05). Furthermore, the incidence of severe preeclampsia was higher at recurrence in patients with rPE compared to their first onset (83.49% vs. 70.64%, P < 0.05), as well as the incidence of severe preeclampsia with chronic hypertension (34.86% vs. 8.26%, P < 0.05). Additionally, the incidence of gestational diabetes and postpartum hemorrhage was higher in patients with rPE compared to their first preeclampsia onset (25.69% vs. 5.50%, P < 0.05; 20.18% vs. 5.83%, P < 0.05). Compared to the first onset of preeclampsia, patients with rPE had an earlier gestational age at delivery (35.42 ± 3.06 weeks vs. 36.60 ± 2.74 weeks, P < 0.05), lower birth weight of neonates (2478.39 ± 828.44 g vs. 2883.71 ± 712.94 g, P < 0.05), and a higher risk of premature birth (67.00% vs. 47.19%, P < 0.05). However, in patients with rPE, the use of LDA delayed the gestational age at delivery, increased the birth weight of the neonate, reduced the premature birth rate, and increased the perinatal survival rate. In conclusion, patients with rPE are at an increased risk of adverse maternal and fetal outcomes. However, the use of LDA during pregnancy effectively improves these outcomes.
摘要：
本研究旨在探讨复发性子痫前期（rPE）的临床特征，并评估低剂量阿司匹林（LDA）在rPE中的预防作用。我们回顾性分析了2016年1月至2022年12月在北京大学第一医院连续两次妊娠并分娩的109例子痫前期患者的资料。我们分析了rPE患者的妊娠结局，并评估了妊娠期间使用LDA是否可以改善这些结局。我们的结果显示，与首次发作先兆子痫相比，rPE患者在怀孕期间的体重指数（BMI）更高，糖尿病发生率更高（29.01±4.70kg/m2vs.27.13±4.25kg/m2，P<0.05；11.01%vs.1.83%,P<0.05)。此外，rPE患者复发时重度先兆子痫的发生率高于首次发病(83.49%vs.70.64%，P<0.05),以及重度子痫前期伴慢性高血压的发病率(34.86%vs.8.26%,P<0.05)。此外,rPE患者的妊娠期糖尿病和产后出血的发生率高于首次先兆子痫（25.69％vs.5.50%,P<0.05;20.18%vs.5.83%,P<0.05)。与第一次先兆子痫相比，rPE患者分娩时孕龄较早(35.42±3.06周vs.36.60±2.74周，P<0.05),新生儿出生体重较低（2478.39±828.44gvs.2883.71±712.94g,P<0.05),早产的风险更高(67.00%vs.47.19%，P<0.05)。然而,在rPE患者中，LDA的使用延迟了分娩时的胎龄，增加了新生儿的出生体重，降低了早产率，提高了围产期存活率。总之,rPE患者发生不良母婴结局的风险增加.然而,妊娠期使用LDA可有效改善这些结局.
